Stock market today: S&P 500 drops for fifth day as focus shifts to Powell’s speech
Investing.com - H.C. Wainwright raised its price target on Sanara MedTech (NASDAQ:SMTI) to $54.00 from $53.00 on Monday, while maintaining a Buy rating following the company’s second-quarter financial results. According to InvestingPro data, the company has shown impressive momentum with a 10.5% return over the past week, while maintaining strong gross profit margins of 91.76%.
Sanara MedTech reported net revenue of $25.8 million for the second quarter of 2025, representing 28% year-over-year growth and exceeding H.C. Wainwright’s projection of $25.4 million. The company posted a net loss of $2.0 million, or ($0.23) per share, which was less than the estimated loss of $2.9 million. This performance aligns with the company’s broader growth trajectory, as InvestingPro analysis shows a robust trailing twelve-month revenue growth of 34.29%.
Revenue from soft tissue repair products reached $22.7 million, up 28% year-over-year, driven primarily by increased demand for CellerateRX Surgical Activated Collagen. This growth was achieved through increased penetration of existing medical facilities, expansion into additional facilities, and development of an independent distribution network in both new and existing U.S. markets.
The company’s bone fusion products generated $3.1 million in revenue, marking a 25% increase year-over-year. H.C. Wainwright noted that Sanara’s Surgical segment could continue to drive topline growth as the company implements its strategy to expand its distribution partner network and add new healthcare facilities.
H.C. Wainwright’s increased revenue projections for the next 12 months (from Q3 2025 to Q2 2026) led to the higher price target of $54 per share, up from the previous target of $53.
In other recent news, Sanara MedTech Inc. reported a strong performance for the second quarter of 2025, showcasing significant growth in both revenue and net income. The company achieved a net revenue of $25.8 million, marking a 28% increase compared to the same period last year. This growth was primarily driven by robust sales in its soft tissue and bone fusion product lines. The positive financial results highlight the company’s successful strategies in expanding its product offerings and market reach. While the earnings report did not mention any mergers or acquisitions, the solid revenue growth indicates a strong operational performance. There were no recent analyst upgrades or downgrades reported for Sanara MedTech. These developments reflect the company’s ongoing efforts to strengthen its market position and financial health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.